FibroGen (FGEN) Expected to Announce Quarterly Earnings on Monday

FibroGen (NASDAQ:FGEN) is expected to be posting its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect FibroGen to post earnings of ($0.14) per share and revenue of $24.91 million for the quarter.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.55 on Monday. The firm has a market cap of $55.88 million, a P/E ratio of -0.45 and a beta of 0.75. The firm’s 50 day moving average price is $0.50 and its 200 day moving average price is $0.42. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a report on Tuesday, December 17th. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. Finally, StockNews.com started coverage on shares of FibroGen in a report on Thursday. They issued a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.